Lanreotide

Approved by the FDA on 16 December 2014, Somatuline is used for well- or moderately differentiated Gastroenteropancreatic Neuroendocrine tumors resembling normal tissue that are unresectable, locally advanced or spreading.

Gastroenteropancreatic Neuroendocrine tumors are a subgroup of nervous- and hormone-system tumors involving organs such as the stomach, pancreas and intestines. The drug is believed to work by mimicking Somatostatin, a hormone secreted in our body with effects primarily on growth. Vomiting was reported as its most common side effect.